Published in J Invest Dermatol on March 01, 2006
Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration (2007) 1.67
Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A (2006) 1.53
Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol (2008) 1.05
Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol (2006) 1.01
Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J Immunol (2015) 0.89
Are increased Foxp3+ regulatory T cells responsible for immunosuppression during HTLV-1 infection? Case reports and review of the literature. BMJ Case Rep (2012) 0.79
Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children. Am J Clin Pathol (2009) 0.79
Immune modulators as therapeutic agents for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk (2010) 0.75
The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed (2015) 0.75
Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 6.61
Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol (2007) 5.99
Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12
Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99
Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol (2004) 2.79
Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol (2004) 2.54
The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity (2012) 2.52
Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol (2003) 2.47
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med (2006) 2.44
TRAF6 is a critical factor for dendritic cell maturation and development. Immunity (2003) 2.36
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
Organ transplantation--how much of the promise has been realized? Nat Med (2005) 2.26
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05
The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity (2006) 2.04
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest (2005) 2.01
Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma (2007) 2.01
Notch signaling augments T cell responsiveness by enhancing CD25 expression. J Immunol (2003) 1.95
Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity (2008) 1.95
PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J Clin Invest (2006) 1.93
The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity (2002) 1.89
Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med (2002) 1.84
Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A (2007) 1.81
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer (2014) 1.76
CTLA4Ig: bridging the basic immunology with clinical application. Immunity (2006) 1.75
Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med (2003) 1.66
Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol (2005) 1.61
Cutting edge: Th2 response induction by dendritic cells: a role for CD40. J Immunol (2002) 1.60
Impaired T cell function in RANTES-deficient mice. Clin Immunol (2002) 1.60
Organ transplantation: halfway through the first century. J Am Soc Nephrol (2004) 1.59
Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol (2005) 1.58
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest (2014) 1.58
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol (2006) 1.54
T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest (2014) 1.53
High-sensitivity detection and quantitative analysis of native protein-protein interactions and multiprotein complexes by flow cytometry. Sci STKE (2007) 1.51
Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol (2006) 1.51
The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest (2008) 1.50
The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol (2003) 1.50
Tregs and transplantation tolerance. J Clin Invest (2004) 1.49
Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol (2004) 1.48
An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest (2013) 1.46
MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection. J Immunol (2008) 1.45
IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells. Front Biosci (2008) 1.45
T cell expression of MyD88 is required for resistance to Toxoplasma gondii. Proc Natl Acad Sci U S A (2008) 1.43
Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol (2006) 1.42
Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol (2008) 1.41
Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proc Natl Acad Sci U S A (2005) 1.38
Defective activation of protein kinase C and Ras-ERK pathways limits IL-2 production and proliferation by CD4+CD25+ regulatory T cells. J Immunol (2006) 1.37
Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. J Immunol (2006) 1.37
An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol (2010) 1.35
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J Immunol (2005) 1.32
CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett (2007) 1.29
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood (2006) 1.28
Presentation of Toxoplasma gondii antigens via the endogenous major histocompatibility complex class I pathway in nonprofessional and professional antigen-presenting cells. Infect Immun (2007) 1.26
Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res (2008) 1.23
Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa. J Am Acad Dermatol (2003) 1.22
Allograft rejection in a new allospecific CD4+ TCR transgenic mouse. Am J Transplant (2003) 1.21
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol (2010) 1.20
Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol (2006) 1.19
Heterologous immunity and homeostatic proliferation as barriers to tolerance. Curr Opin Immunol (2004) 1.19
Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J Clin Invest (2010) 1.17
A role for IL-27 in limiting T regulatory cell populations. J Immunol (2011) 1.17
Regulation of T-cell responses by PTEN. Immunol Rev (2008) 1.15
Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J Clin Invest (2012) 1.15
TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res (2013) 1.15
Airway infiltration of CD4+ CCR6+ Th17 type cells associated with chronic cigarette smoke induced airspace enlargement. Immunol Lett (2008) 1.14
The innate immune system in allograft rejection and tolerance. J Immunol (2007) 1.13
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood (2004) 1.12
Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest (2002) 1.12
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. J Am Acad Dermatol (2009) 1.10
Vascular endothelium does not activate CD4+ direct allorecognition in graft rejection. J Immunol (2004) 1.10
Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation. J Exp Med (2002) 1.07
New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol (2011) 1.06
Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A (2009) 1.06
Astrocytes as antigen-presenting cells: expression of IL-12/IL-23. J Neurochem (2005) 1.05
Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol (2008) 1.05
The proliferative capacity of individual naive CD4(+) T cells is amplified by prolonged T cell antigen receptor triggering. J Exp Med (2002) 1.05
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol (2005) 1.03
The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol (2010) 1.03
TNF receptor-associated factor 6 deficiency during hemopoiesis induces Th2-polarized inflammatory disease. J Immunol (2003) 1.03
Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol (2002) 1.03